Phase 2 Castrate Resistant Prostate Cancer Clinical Trials
8 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals188 enrolled29 locationsNCT07206056
Recruiting
Phase 2
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
Prostate CancerProstate CarcinomaMetastatic Castration-resistant Prostate Cancer+1 more
University of California, San Francisco48 enrolled1 locationNCT05766371
Recruiting
Phase 1Phase 2
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Breast CancerOvarian CancerEndometrial Cancer+8 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 2
Dose Optimisation and Prostate-Specific Membrane Antigen (PSMA) Receptor intensification with 177Lu-PSMA Therapy: A Randomised Phase II trial: OPTIMAL-PSMA
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
St Vincent's Health Network120 enrolled1 locationACTRN12625000971437
Recruiting
Phase 2
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Metastatic Castrate Resistant Prostate CancerBARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2RAD51B, RAD51C, RAD51D, or RAD54L Mutations
VA Office of Research and Development100 enrolled18 locationsNCT04038502
Recruiting
Phase 1Phase 2
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Renal Cell CancerCastrate Resistant Prostate Cancer
Portage Biotech90 enrolled3 locationsNCT04969315
Recruiting
Phase 2
Evolocumab in Metastatic Castration-Resistant Prostate Cancer
Metastatic Castrate Resistant Prostate Cancer
National Health and Medical Research Council30 enrolled3 locationsACTRN12622001003763
Terminated
Phase 2
A single arm, prospective Phase II study of Split-Course Pelvic Radiotherapy for Locally Progressive, Castrate Resistant Prostate Cancer
Castrate Resistant Prostate Cancer
Radiation Oncology Services - Mater Centre20 enrolled3 locationsACTRN12614000858695